Drugs News and Research

RSS

Study: 75% of men with diabetes will develop some degree of ED

Erectile dysfunction is one of the most prevalent diabetes-induced complications in men; current estimates suggest that as many as 75% of men with diabetes will develop some degree of ED, and in many cases diabetics develop more severe forms of ED that are less responsive to standard drugs.

7 Apr 2010

$13,000 per year AIDS drugs Reyataz: AHF calls upon BMS to lower price

AIDS Healthcare Foundation (AHF) is pressing New York-based drug firm Bristol-Myers Squibb (BMS) to lower the price of its key AIDS drug, Reyataz—currently priced at over $13,000 per year—for lifesaving, but financially hard-hit AIDS Drug Assistance Programs (ADAPs) nationwide.

7 Apr 2010

Children with FASD show high prevalence of developing epilepsy

Children with Fetal Alcohol Spectrum Disorder show a very high prevalence of developing epilepsy and having seizures, according to a national study by Queen's University researchers.

7 Apr 2010

Newer treatments, closer monitoring of childhood cancer may improve longevity

Although more children today are surviving cancer than ever before, young patients successfully treated in the 1970s and 80s may live a decade less, on average, than the general population, according to a study from Dana-Farber Cancer Institute and the Harvard School of Public Health.

7 Apr 2010

GE Capital, Healthcare Financial Services supports CCS Medical with $35M revolving line of credit

GE Capital, Healthcare Financial Services today announced it has provided a $35 million revolving line of credit to CCS Medical, Inc. The loan will be used to refinance existing debt, provide working capital and support growth initiatives following CCS Medical's exit from Chapter 11 bankruptcy protection on March 31, 2010.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Health officials monitor cases of pandemic H1N1 flu in the Southeast

The continued spread of H1N1 influenza virus this spring is cause to pay heed to upper-respiratory maladies such as congestion, runny nose and cough, says David Kimberlin, M.D., a preeminent influenza specialist who co-directs the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

6 Apr 2010

Prescription overdoses are second leading cause of unintentional deaths in US

"Unintentional poisoning is now the second leading cause of unintentional death in the US," reports Dr. Jeffrey H. Coben of West Virginia University School of Medicine in Morgantown. Among people 35 to 54 years old, unintentional poisoning surpassed motor vehicle crashes as the leading cause of unintentional death in 2005.

6 Apr 2010

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells.

6 Apr 2010

U.S. Marshals seizes unapproved drug products

At the request of the U.S. Food and Drug Administration, U.S. Marshals on March 31 seized a range of consumer products, including creams, capsules, tablets, gum, throat spray, and shampoos from a Haywood, Wis., manufacturer.

6 Apr 2010

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

NeurogesX, Inc. announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia, the nerve pain that can occur after shingles.

6 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

Prescription drug abuse reaches epidemic proportions

Poisoning is now the second leading cause of unintentional injury death in the U.S. While several recent high-profile Hollywood celebrity cases have brought the problem to public attention, the rates of unintentional poisoning deaths have been on the rise for more than 15 years.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye Pharmaceutical subsidiary ("Erye") recently received approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium.

5 Apr 2010

60 Minutes examines PEPFAR in Uganda

CBS News' 60 Minutes reports from Uganda about how PEPFAR has helped people living with HIV/AIDS throughout the country and the challenges Uganda still faces in fighting the spread of the virus. The show includes interviews with Peter Mugyenyi of the Joint Clinical Research Center in Kampala, Uganda, and other doctors on the ground, who discuss how HIV-positive children and adults are alive today as a result of PEPFAR and how the program has helped to improve the way Africans view the United States.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010